23-Valent Pneumococcal Polysaccharide Vaccine Market by Dose Type (Single Dose Vial, and Pre-filled Syringe), and by Age-Group (Children [2-10 Years], Adult [10-64 Years], and Geriatrics [65 Years and Above]) - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Report Number: 3517
  • Publish Date: 23-May-2018

Reports Overview

Pneumococcal is an infectious disease caused by the streptococcus pneumoniae bacteria. Pneumococcal may cause different types of illnesses such as ear infection, meningitis, and others. There are vaccines available that can prevent pneumococcal infection such as pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. Pneumococcal polysaccharide vaccines are recommended mostly for adults who suffer from pneumococcal infection.

Increase in geriatric population, rise in the incidence of bacterial infections, and advancements in medical technology are the major factors that drive the market growth. However, stringent government regulations for the approval of vaccines are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA is expected to provide new growth opportunities for the market during the analysis period.

The 23-Valent pneumococcal polysaccharide vaccine market is segmented on the basis of dose type, age-group, and geography. Based on dose type the market is segmented into single dose vial and pre-filled syringe. Based on age-group the market is divided into children (2-10 years), adults (10-64 years), and geriatrics (65 years and above). By geography, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global 23-valent pneumococcal polysaccharide vaccine market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report offers a quantitative analysis to assist stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments determines various products available in the market.
  • Key players have been profiled and their strategies thoroughly analyzed to predict the competitive market outlook.

23-valent Pneumococcal Polysaccharide Vaccine Market Key Segments:

By Dose Type

  • Single Dose Vial
  • Pre-Filled Syringe

By Age-Group

  • Children (2-10 years)
  • Adults (10-64 years)
  • Geriatrics (65 years and above)

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • The Middle East
    • Africa

List of players profiled in the report

  • Pfizer Inc.
  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • Merck & Co.
  • AstraZeneca
  • Baxter International Inc.
  • Beijing Minhai Biotechnology
  • Serum Institute of India
  • Biogen Inc.
  • Eli Lilly and Company

Table Of Content

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET, BY DOSE TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SINGLE DOSE VIAL

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. PRE-FILLED SYRINGE

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET, BY AGE-GROUP

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CHILDREN (2-10 YEARS)

5.2.1. Market size and forecast

5.3. ADULTS (10-64 YEARS)

5.3.1. Market size and forecast

5.4. GERIATRICS (65 YEARS AND ABOVE)

5.4.1. Market size and forecast

Chapter: 6 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market by Dose Type
6.2.5. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market by Age-Group

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market by Dose Type
6.3.5. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market by Age-Group

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market by Dose Type
6.4.5. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market by Age-Group

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Market by Dose Type
6.5.5. LAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Market by Age-Group

Chapter: 7 COMPANY PROFILES

7.1. PFIZER INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. SANOFI S.A.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. MERCK & CO.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ASTRAZENECA

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BAXTER INTERNATIONAL INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. BEIJING MINHAI BIOTECHNOLOGY

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. SERUM INSTITUTE OF INDIA

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. BIOGEN INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. ELI LILLY AND COMPANY

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

There are no reviews yet.

Be the first to review “23-Valent Pneumococcal Polysaccharide Vaccine Market Report 2018”